Tuesday, December 15, 2009 | 1:00 PM - 5:00 PM
Speakers: Haim Einat (University of Minnesota), Rif S. El-Mallakh (University of Louisville School of Medicine), Todd Gould (University of Maryland School of Medicine), Alexander B. Niculescu, III (Indiana University School of Medicine)
This symposium will highlight new developments in Bipolar disorder models and biomarker identification, and will reveal how these new strategies can further our understanding of the disease and our ability to identify new therapies.
Tuesday, January 26, 2010 | 9:00 AM - 5:00 PM
Organizers: Lawrence P. Wennogle (Intra-Cellular Therapies, Inc.) and Peter Hutson (Merck and Co., Inc.)
The symposium will focus on phosphodiesterase (PDE) inhibitors for schizophrenia and cognitive disorders and review the theoretical basis of different PDE isoforms as well as the progress towards human clinical testing of these agents.
May 19 - 21, 2010 | Spain
Keynote Speaker: J. Michael Bishop (The G.W. Hooper Research Foundation, University of California, San Francisco)
This conference will discuss advancements, challenges, and future steps in research leading to an individualized understanding of cancer and its translation into personalized clinical care.
October 28 - 30, 2009
Organizers: Debra L. Laskin (Rutgers University), Howard Kipen (UMDNJ-Robert Wood Johnson Medical School),Val Vallyathan (NIOSH/CDC), Vince Castranova (NIOSH/CDC), Andrew J. Gow (Rutgers University), Jeffrey D. Laskin (UMDNJ-Robert Wood Johnson Medical School), and Diane E. Heck (New York Medical College)
The symposium will integrate basic science and clinical research so that both bench researchers and clinicians can discuss the role of reactive oxygen and nitrogen species in inflammation and lung disease.
Tuesday, October 27, 2009 | 1:00 PM - 5:00 PM
Speakers: Suzanne M. de la Monte (Brown Medical School), William L. Klein (Northwestern University), José A. Luchsinger (Columbia University), Mark Mattson (National Institute on Aging, NIH)
Alzheimer’s disease (AD) has been called Type 3 diabetes, unique to the brain; others suggest that diabetes is a risk factor for AD. This symposium will discuss the significance of cerebral metabolic disturbances in Alzheimer's disease.
October 21 - 24, 2009
Organizers: Elliott Vichinsky (Children's Hospital and Research Center, Oakland, CA), Ellis Neufeld (Children's Hospital Boston)
This symposium will illuminate many unsolved but critically important issues in the understanding and treatment of thalassemia, thus offering the scientific, clinical, caregiving, and patient communities the most up-to-date exchange on the current and future perspectives of the disease.
Wednesday, September 30, 2009 | 8:30 AM - 7:00 PM
Chair: J. William Langston (The Parkinson's Institute and Clinical Center)
Held in partnership with the Michael J. Fox Foundation, this meeting will highlight novel advances in basic and translational research that impact understanding of Parkinson's Disease and its treatment.
|
eBriefing
Organizers: Anthony Atala (Wake Forest University), Stacie Bloom (New York Academy of Sciences), Yilin Cao (Shanghai Jiao Tong University), Anita Chong (The University of Chicago), Stefanie Dimmeler (University of Frankfurt), Michael P. Sheetz (Columbia University), Qiming Zhan (Chinese Academy of Medical Sciences), Alex Zhang (Sanofi Aventis), Chunhua Zhao (Chinese Academy of Medical Sciences)
A recent international conference in Beijing focused on exciting developments in fields like stem cell biology, tissue engineering, and xenotransplantation. A new eBriefing documents the event.
eBriefing
Keynote Speaker: William W. Li (The Angiogenesis Foundation)
Judah Folkman pioneered the concept of treating cancer by attacking the tumor's supply lines—the capillary blood vessels that feed the tumor. This eBriefing reports on a recent meeting focusing on new findings and persistent challenges in the field.
eBriefing
Organizer: Howard Fillit (Alzheimer's Drug Discovery Foundation)
There's no consensus about what cognitive aging is, but mental decline clearly affects most of us as we grow older. This eBriefing explores how cognitive aging relates to other neurodegenerative disorders and how it may be managed.
eBriefing
Speakers: David Riddell (Wyeth Research), Robert Vassar (Northwestern University), Lisa McConlogue (Elan Pharmaceuticals), Ishrut Hussain (GlaxoSmithKline R&D), and Jordan Tang (Oklahoma Medical Research Foundation)
BACE1 is the enzyme that generates the toxic peptide amyloid-β in the brain. Researchers convened at the Academy to discuss efforts to develop a drug that targets BACE1 and prevents amyloid plaque build-up.
eBriefing
Organizers: Raymond Donnelly and Amy Rosenberg (U.S. Food and Drug Administration), Howard Young (National Cancer Institute)
Cytokine-based therapeutics promise new treatments for cancer, autoimmune disorders, and infectious diseases. Can researchers find more effective ways to turn these intercellular messengers into life-saving medicines?
Webinar Archive
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
|